Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Immuneering Corporation
Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
August 29, 2024
From
Immuneering Corporation
Via
GlobeNewswire
Tickers
IMRX
Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates
August 06, 2024
From
Immuneering Corporation
Via
GlobeNewswire
Tickers
IMRX
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer
July 31, 2024
From
Immuneering Corporation
Via
GlobeNewswire
Tickers
IMRX
Immuneering to Present at the Jefferies Global Healthcare Conference
May 29, 2024
From
Immuneering Corporation
Via
GlobeNewswire
Tickers
IMRX
Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates
May 07, 2024
From
Immuneering Corporation
Via
GlobeNewswire
Tickers
IMRX
Immuneering Recognizes Melanoma Awareness Month
May 06, 2024
From
Immuneering Corporation
Via
GlobeNewswire
Tickers
IMRX
IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
April 09, 2024
From
Immuneering Corporation
Via
GlobeNewswire
Tickers
IMRX
Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference
April 03, 2024
From
Immuneering Corporation
Via
GlobeNewswire
Tickers
IMRX
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
March 27, 2024
From
Immuneering Corporation
Via
GlobeNewswire
Tickers
IMRX
Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors
March 14, 2024
From
Immuneering Corporation
Via
GlobeNewswire
Tickers
IMRX
Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors
March 12, 2024
From
Immuneering Corporation
Via
GlobeNewswire
Tickers
IMRX
Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors
March 11, 2024
From
Immuneering Corporation
Via
GlobeNewswire
Tickers
IMRX
Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024
March 05, 2024
From
Immuneering Corporation
Via
GlobeNewswire
Tickers
IMRX
Immuneering to Participate in the Cowen 44th Annual Health Care Conference
March 04, 2024
From
Immuneering Corporation
Via
GlobeNewswire
Tickers
IMRX
Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
March 01, 2024
From
Immuneering Corporation
Via
GlobeNewswire
Tickers
IMRX
Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer
February 20, 2024
From
Immuneering Corporation
Via
GlobeNewswire
Tickers
IMRX
Immuneering Announces Participation in February Investor Conferences
February 01, 2024
From
Immuneering Corporation
Via
GlobeNewswire
Tickers
IMRX
Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
December 12, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Tickers
IMRX
Immuneering to Present at the 35th Annual Piper Sandler Healthcare Conference
November 20, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Tickers
IMRX
Immuneering Reports Third Quarter 2023 Financial Results and Provides Business Updates
November 09, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Tickers
IMRX
Immuneering Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference
October 12, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Tickers
IMRX
Immuneering to Present Preclinical Data on IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 04, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Tickers
IMRX
Immuneering to Present at the Morgan Stanley Healthcare Conference
September 06, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Tickers
IMRX
Immuneering Reports Second Quarter 2023 Financial Results and Provides Business Updates
August 03, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Tickers
IMRX
Immuneering Completes Dose Escalation in the IMM-1-104 Phase 1 Clinical Trial for RAS-Mutant, Advanced Solid Tumors
June 05, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Tickers
IMRX
Immuneering to Present at the Jefferies Healthcare Conference
May 30, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Tickers
IMRX
Immuneering Reports First Quarter 2023 Financial Results and Provides Business Updates
May 04, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Tickers
IMRX
Immuneering Announces $30 Million Underwritten Offering
April 18, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Tickers
IMRX
Immuneering Announces Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program; Accelerates Study Timeline
April 18, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Tickers
IMRX
Immuneering to Present at the 22nd Annual Needham Virtual Healthcare Conference
April 12, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Tickers
IMRX
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.